This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Time-to-event assessment for the discovery of the proper prognostic value of clinical biomarkers optimized for COVID-19 (preprint)
medrxiv; 2021.
Preprint
in English
| medRxiv | ID: ppzbmed-10.1101.2021.07.09.21260262
ABSTRACT
In the early days of the pandemic, clinical biomarkers for COVID -19 have been investigated to predict patient mortality. A decision tree has been proposed previously comprising three variables, i.e., lactic dehydrogenase (LDH), high-sensitivity C-reactive protein (CRP), and lymphocyte percentage, with more than 90% accuracy in a public cohort. In this work, we highlighted the importance of the cohort made publicly available and complemented the findings by incorporating further evaluation. Results confirmed poor short-term prognosis to abnormal levels of some laboratorial indicators, such as LDH, CRP, lymphocytes, interleukin-6, and procalcitonin. In addition, our findings provide insights into COVID-19 research, such as key levels of fibrin degradation products, which are directly associated with the Dimerized plasmin fragment D and could indicate active coagulation and thrombosis. Still, we highlight here the prognostic value of interleukin-6, a cytokine that induces inflammatory response and may serve as a predictive biomarker.
Full text:
Available
Collection:
Preprints
Database:
medRxiv
Main subject:
Thrombosis
/
COVID-19
/
Laboratory Infection
Language:
English
Year:
2021
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS